Today’s formulation challenges are as diverse as they are demanding, from increasingly insoluble new chemical entities (NCEs) to highly bitter drugs, to increased regulatory emphasis on patient acceptance. Arriving at a final dosage form that has commercial potential is a more complex proposition than ever.
